KARE Biosciences

KARE BiosciencesKARE BiosciencesKARE Biosciences

KARE Biosciences

KARE BiosciencesKARE BiosciencesKARE Biosciences
  • Home
  • About Us
    • Pipeline
    • Our Science
    • Our Publications
    • Our Patents
  • News
    • Presentations
    • Our Blog
  • Our Team
  • Contact
  • More
    • Home
    • About Us
      • Pipeline
      • Our Science
      • Our Publications
      • Our Patents
    • News
      • Presentations
      • Our Blog
    • Our Team
    • Contact
  • Home
  • About Us
  • News
  • Our Team
  • Contact

Our patents

International Patent:


Title: Dual Antagonist of PGD2/DPr2 and thromboxane A2/TPr receptor and use for the treatment of maladaptive immune response or thrombotic diathesis

International Application No. PCT/IB2021/052693

Filed March 31, 2021


US Provisional Patents: 


Title: Use Of a Dual Receptor Antagonist of Prostaglandin D2/DP2 Receptors and Thromboxane A2/TP Receptors for Prophylaxis and/or Treatment of Tissue Fibrosis in Mammals

US PTO Application #63/092,921

Filed October 16, 2020


Title: Use of ramatroban or other blockers of pgd2/dp2 and/or thromboxane a2 receptor for treatment of diseases and conditions related to infection, vascular injury, inflammation, vasculitis, platelet activation, coagulopathy, and thrombosis 

US PTO Application #63/027,751

Filed May 20, 2020


Title: Use Of A CRTH2 Antagonist Such As Ramatroban As A Therapeutic Agent For Treatment Of Adults With Viral Infection Including Covid-19

US PTO Application #63/005,205 

Filed April 3, 2020


Title: Use of Ramatroban as a therapeutic agent for prevention and treatment of viral infections including COVID-19

US PTO Application #63/003,286 

Filed March 31, 2020

Copyright © 2022 KARE Biosciences - All Rights Reserved.


Powered by GoDaddy